<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393285</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-3039</org_study_id>
    <nct_id>NCT04393285</nct_id>
  </id_info>
  <brief_title>Abemaciclib and Letrozole to Treat Endometrial Cancer</brief_title>
  <official_title>A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II single arm trial to determine the percentage of patients without evidence&#xD;
      of disease progression on abemaciclib and letrozole in advanced stage, persistent or&#xD;
      recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until either&#xD;
      unacceptable toxicity, progression of disease, or investigator/patient request for&#xD;
      withdrawal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of protocol entry to date of first documented progression up to 6 months</time_frame>
    <description>To evaluate the efficacy in terms of the probability of surviving progression free for at least 6 months (PFS at 6 mo)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>From date of protocol entry to date of first response assessed up to 5 years</time_frame>
    <description>To determine the proportion responding by RECIST v1.1 in patients with advanced, persistent, or recurrent endometrioid endometrial cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression or death</measure>
    <time_frame>From date of protocol entry to date of progression or death assessed up to 5 years</time_frame>
    <description>To estimate the time to disease progression or death (PFS and OS endpoints).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Assessment of Adverse Events</measure>
    <time_frame>Every 4 weeks assessed up to 5 years</time_frame>
    <description>To describe the toxicities in patients receiving combination therapy with letrozole and abemaciclib</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Protein expression analysis of Cyclin D and E Pathway</measure>
    <time_frame>At time of primary and secondary outcome analysis up to 5 years</time_frame>
    <description>Perform multiplexed protein expression analysis at a single cell level using imaging mass cytometry (IMC), exploring the relationship to response, and assessing for longitudinal changes upon progression/relapse. Cyclin D and E Pathway: Protein expression of CCND1, CDK4, CDK6, RB1, phospho-RB1, CDKN2A, CCNE1, CCNE2, CDK2, CCND3</description>
  </other_outcome>
  <other_outcome>
    <measure>Protein expression analysis of Immune Cell Infiltration and activity</measure>
    <time_frame>At time of primary and secondary outcome analysis up to 5 years</time_frame>
    <description>Perform multiplexed protein expression analysis at a single cell level using imaging mass cytometry (IMC), exploring the relationship to response, and assessing for longitudinal changes upon progression/relapse. Immune cell infiltration and activity: CD45, CD3, CD8, CD4, FoxP3, PD-1, Tim-3, CTLA-4, CD25, Ki67.</description>
  </other_outcome>
  <other_outcome>
    <measure>Protein expression analysis of sex hormone/insulin/IGF pathway</measure>
    <time_frame>At time of primary and secondary outcome analysis up to 5 years</time_frame>
    <description>Perform multiplexed protein expression analysis at a single cell level using imaging mass cytometry (IMC), exploring the relationship to response, and assessing for longitudinal changes upon progression/relapse.&#xD;
Sex hormone/insulin/IGF pathway: Protein expression of ER (ESR1), PR, IR, IGF1R, and phospho-IGF1R/IR</description>
  </other_outcome>
  <other_outcome>
    <measure>Cyclin D1 3'UTR mutations</measure>
    <time_frame>At time of primary and secondary outcome analysis up to 5 years</time_frame>
    <description>Determine the frequency of Cyclin D1 3'UTR mutations and correlatioin with response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Estradiol levels</measure>
    <time_frame>At time of primary and secondary outcome analysis up to 5 years</time_frame>
    <description>Compare the pre- and post-treatment circulating estradiol levels, and association with response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin levels</measure>
    <time_frame>At time of primary and secondary outcome analysis up to 5 years</time_frame>
    <description>Compare the pre- and post-treatment circulating insulin levels, and association with response.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Abemaciclib and Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study treatment will consist of abemaciclib 150mg orally twice a day and letrozole 2.5mg orally once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Abemaciclib 150mg orally twice a day</description>
    <arm_group_label>Abemaciclib and Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole 2.5mg orally once a day</description>
    <arm_group_label>Abemaciclib and Letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must have advanced (FIGO 2014 Stage III or IV), persistent, or recurrent&#xD;
             endometrial carcinoma, which is not likely to be curable by surgery or radiotherapy.&#xD;
             Histologic confirmation of recurrent disease is required. For cases of persistent&#xD;
             disease, histologic confirmation of the primary disease with radiologic evidence of&#xD;
             progression is required.&#xD;
&#xD;
          2. Patients must have endometrioid histology (all grades allowed) based on hysterectomy&#xD;
             or biopsy specimen (Hormone receptor status is not required for enrollment).&#xD;
&#xD;
             Sites are required to report results of previous MMR, MSI, and ER/PR status testing in&#xD;
             Medidata Rave if available.&#xD;
&#xD;
          3. All patients must have measurable disease. Measurable disease is defined by RECIST&#xD;
             version 1.1. Measurable disease is defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded). Each&#xD;
             lesion must be greater than or equal to 10mm when measured by CT, MRI or caliper&#xD;
             measurement by clinical exam; or greater than or equal to 20mm when measured by chest&#xD;
             x-ray. Lymph nodes must be greater than or equal to 15mm in short axis when measured&#xD;
             by CT or MRI.&#xD;
&#xD;
             Patient must have at least one &quot;target lesion&quot; to be used to assess response on this&#xD;
             protocol as defined by RECIST 1.1. Tumors within a previously irradiated field will be&#xD;
             designated as &quot;non-target&quot; lesions unless progression is documented or a biopsy is&#xD;
             obtained to confirm persistence at least 90 days following completion of radiation&#xD;
             therapy.&#xD;
&#xD;
          4. Prior chemotherapy in the adjuvant setting for Stage I, II, or III is permitted. Prior&#xD;
             chemoradiotherapy for a pelvic recurrence is permitted.&#xD;
&#xD;
             Note: Chemotherapy in the setting of Stage IV disease is permitted but the patient&#xD;
             must be without evidence of disease at the completion of chemotherapy and have at&#xD;
             least six months of progression-free survival since the completion of chemotherapy&#xD;
             before detection of the recurrent cancer for which she is receiving treatment on this&#xD;
             protocol.&#xD;
&#xD;
             Prior immunotherapy and/or targeted therapy is allowed in addition to, in combination&#xD;
             with, in lieu of, or subsequent to prior chemotherapy.&#xD;
&#xD;
             Regardless of circumstances, no more than one prior chemotherapy regimen (including&#xD;
             chemo-radiotherapy) is permitted, and no more than one additional systemic therapy is&#xD;
             permitted. Hence, eligible patient may have received 0, 1, or 2 prior lines of&#xD;
             systemic therapy and for women who received two prior lines of therapy, only one of&#xD;
             them may have included chemotherapy.&#xD;
&#xD;
             Patients who received prior chemotherapy, immunotherapy or targeted therapy must have&#xD;
             recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≤1) from the&#xD;
             acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral&#xD;
             neuropathy prior to enrollment. A washout period of at least 21 days is required&#xD;
             between last systemic therapy dose and initiation of therapy.&#xD;
&#xD;
             Patients who received radiotherapy must have completed and fully recovered from the&#xD;
             acute effects of radiotherapy. A washout period of at least 14 days is required&#xD;
             between end of radiotherapy and initiation of therapy.&#xD;
&#xD;
          5. Patient must be able to swallow oral medications.&#xD;
&#xD;
          6. Patient must have an ECOG performance status of 0 to 1.&#xD;
&#xD;
          7. Patients must have adequate organ and marrow function as defined below NOTE:&#xD;
             Institutional/laboratory upper limit of normal = ULN Institutional/laboratory lower&#xD;
             limit of normal = LLN&#xD;
&#xD;
             Bone marrow function:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) greater than or equal to 1500/mcl&#xD;
&#xD;
               -  Platelets greater than or equal to 100,000 cells/mcl&#xD;
&#xD;
               -  Hemoglobin greater than or equal to 8 g/dL (Patients may receive erythrocyte&#xD;
                  transfusions to achieve this hemoglobin level at the discretion of the&#xD;
                  investigator. Initial treatment must not begin earlier than the day after&#xD;
                  erythrocyte transfusion).&#xD;
&#xD;
             Renal function:&#xD;
&#xD;
             • Creatinine less than or equal to 1.5 x ULN&#xD;
&#xD;
             Hepatic function:&#xD;
&#xD;
               -  Bilirubin less than or equal to 1.5 x ULN (Patients with Gilbert's syndrome with&#xD;
                  a total bilirubin ≤2 times ULN and direct bilirubin within normal limits are&#xD;
                  permitted).&#xD;
&#xD;
               -  ALT (alanine aminotransferase) and AST (aspartate aminotransferase) less than or&#xD;
                  equal to 3 x ULN&#xD;
&#xD;
               -  Alkaline phosphatase less than or equal to 2.5 x ULN&#xD;
&#xD;
               -  Albumin greater than or equal to 2.8 g/dL&#xD;
&#xD;
          8. Patients must have signed an approved informed consent and authorization permitting&#xD;
             release of personal health information.&#xD;
&#xD;
          9. Patients must be at least 18 years of age.&#xD;
&#xD;
         10. Patients of childbearing potential must have a negative serum pregnancy test prior to&#xD;
             the study entry and be practicing a highly effective form of contraception during the&#xD;
             study treatment and for 8 weeks after stopping the treatment.&#xD;
&#xD;
        Highly effective contraception methods include combination of any of the following (NOTE:&#xD;
        Estrogen containing contraceptives are prohibited):&#xD;
&#xD;
          -  Use of oral, injected, or implanted hormonal methods of contraception or;&#xD;
&#xD;
          -  Placement of an intrauterine device (IUD) or intrauterine system (IUS);&#xD;
&#xD;
          -  Barrier methods of contraception: condom or occlusive cap (diaphgram or cervical/vault&#xD;
             caps) with spermicidal foam/gel/film/cream/vaginal suppository;&#xD;
&#xD;
          -  Total abstinence or;&#xD;
&#xD;
          -  Male/female sterilization. Women are considered post-menopausal and not of&#xD;
             child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea&#xD;
             with an appropriate clinical profile (e.g., age appropriate, history of vasomotor&#xD;
             symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy)&#xD;
             or tubal ligation at least six weeks prior to randomization. In the case of&#xD;
             oophorectomy alone, only when the reproductive status of the woman has been confirmed&#xD;
             by follow up hormone level assessment is she considered not of child-bearing&#xD;
             potential.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Patients who have previously received any CDK4/6 inhibitor.&#xD;
&#xD;
          2. Patients with clear cell, serous, carcinosarcoma, mixed histology endometrial cancers,&#xD;
             or uterine sarcomas.&#xD;
&#xD;
          3. Known intolerance or hypersensitivity to abemaciclib or letrozole.&#xD;
&#xD;
          4. Patients who have previously received hormonal therapy for endometrial cancer.&#xD;
&#xD;
          5. Patients with concomitant invasive malignancy or a history of other invasive&#xD;
             malignancies, with the exception of non-melanoma skin cancer, are excluded if there is&#xD;
             any evidence of other malignancy being present within the past five years. Patients&#xD;
             are also excluded if their previous cancer treatment contraindicates this protocol.&#xD;
&#xD;
          6. Patients receiving chronic treatment with systemic steroids or another&#xD;
             immunosuppressive agent.&#xD;
&#xD;
          7. Patients with active systemic bacterial infection (requiring intravenous [IV]&#xD;
             antibiotics at time of initiating study treatment, fungal infection, or detectable&#xD;
             viral infection (such as known human immunodeficiency virus positivity or with known&#xD;
             active hepatitis B or C [for example, hepatitis B surface antigen positive]).&#xD;
             Screening is not required for enrollment.&#xD;
&#xD;
          8. Patients with a serious pre-existing medical condition(s) that would preclude&#xD;
             participation in this study (for example: interstitial lung disease, severe dyspnea at&#xD;
             rest or requiring oxygen therapy, severe renal impairment (i.e. estimated creatinine&#xD;
             clearance &lt;30ml/min), history of major surgical resection involving the stomach or&#xD;
             small bowel, or preexisting Crohn's disease or ulcerative colitis or pre-existing&#xD;
             chronic condition resulting in baseline grade 2 or higher diarrhea).&#xD;
&#xD;
          9. Patients with a known history of cardiac disease. This includes:&#xD;
&#xD;
               -  Uncontrolled hypertension, defined as systolic greater than 150mm Hg or diastolic&#xD;
                  greater than 90mm Hg despite antihypertensive medications&#xD;
&#xD;
               -  Myocardial infarction or unstable angina within 6 months prior to registration.&#xD;
&#xD;
               -  New York Heart Association (NYHA) Class II or greater congestive heart failure.&#xD;
&#xD;
               -  History of serious ventricular arrhythmia (i.e. ventricular tachycardia or&#xD;
                  ventricular fibrillation) or serious cardiac arrhythmia requiring medication,&#xD;
                  syncope of cardiovascular etiology or sudden cardiac arrest. This does not&#xD;
                  include asymptomatic atrial fibrillation with controlled ventricular rate.&#xD;
&#xD;
               -  Cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) within 6&#xD;
                  months prior to the first date of study therapy.&#xD;
&#xD;
         10. Patients who are pregnant or breast-feeding.&#xD;
&#xD;
         11. Patients with known central nervous system metastases.&#xD;
&#xD;
         12. Patients with known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         13. Patients with an impairment of gastrointestinal function or gastrointestinal disease&#xD;
             that may significantly alter the absorption of abemaciclib (i.e. ulcerative disease;&#xD;
             uncontrolled nausea, vomiting and/or diarrhea; malabsorption syndrome; clinical signs&#xD;
             and symptoms of gastrointestinal obstruction; and/or patients who require parenteral&#xD;
             hydration and/or nutrition).&#xD;
&#xD;
         14. Patients who plan to receive live attenuated vaccines within 1 week of start of&#xD;
             abemaciclib and during the study. Patients should also avoid close contact with others&#xD;
             who have received live attenuated vaccines. Examples of live attenuated vaccines&#xD;
             include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever,&#xD;
             varicella, and TY21a typhoid vaccines.&#xD;
&#xD;
         15. Patients with active bleeding or pathologic conditions that carry high risk of&#xD;
             bleeding such as known bleeding disorder or coagulopathy.&#xD;
&#xD;
         16. Patients with history of unprovoked venous thrombosis unless taking anticoagulation&#xD;
             treatment for duration of trial.&#xD;
&#xD;
         17. Patients who are currently part of or have participated in any clinical investigation&#xD;
             with an investigational drug within 30 days prior to dosing.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marilyn Huang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Klein, MEd</last_name>
    <phone>2158540770</phone>
    <email>jklein@gog.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanie Broemmelsiek</last_name>
      <email>jbroemmelsiek@health.southalabama.edu</email>
    </contact>
    <investigator>
      <last_name>Rodney Rocconi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alaska Women's Cancer Care</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Fulcher</last_name>
      <email>christina.fulcher@providence.org</email>
    </contact>
    <investigator>
      <last_name>Melissa Hardesty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Smillow Cancer Care at Greenwich Hospital</name>
      <address>
        <city>Greenwich</city>
        <state>Connecticut</state>
        <zip>06830</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baker Lisa</last_name>
      <email>lisa.baker@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Gloria Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Baker</last_name>
      <email>lisa.baker@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Gloria Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Baker</last_name>
      <email>lisa.baker@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Gloira Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Health Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Geckler</last_name>
      <email>d.geckler@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Martina Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami - Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Garcia</last_name>
      <email>rxg1051@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Marilyn Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advent Health - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Coakley</last_name>
      <email>susan.coakley@adventhealth.com</email>
    </contact>
    <investigator>
      <last_name>Robert Holloway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Dimayuga</last_name>
      <email>dimayum@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Timmy Nguyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lewis Cancer &amp; Research Pavilion</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joni Shortt</last_name>
      <email>SHORTTJ@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>Sarah Gill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Dolan</last_name>
      <email>pdolan@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>John Moroney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shar Ellison</last_name>
      <email>swelli2@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Dietrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Carney</last_name>
      <email>mcarney@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>John Schorge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massechusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Allen</last_name>
      <email>indsey.allen@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Zweizig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Velfling</last_name>
      <email>Christina.Velfling@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Rebecca Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Bicomong</last_name>
      <email>mb1444@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Aliza Leiser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Kiledjian</last_name>
      <email>pkiledjian@holyname.org</email>
    </contact>
    <contact_backup>
      <email>pkiledjian@holyname.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sharon Lewin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reena Vattakalam</last_name>
      <email>rmv2110@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Bingham</last_name>
      <email>binghame@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Mary Cunningham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists and Research Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Powell</last_name>
      <email>melissa.powell@ocsri.org</email>
    </contact>
    <investigator>
      <last_name>Michael Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reading Hospital-McGlinn Cancer Institute</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Trexler</last_name>
      <email>Kim.Trexler@towerhealth.org</email>
    </contact>
    <investigator>
      <last_name>Bernice Robinson-Bennett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Center Lexington</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Higgins</last_name>
      <email>Lauren.Higgins@bhsi.com</email>
    </contact>
    <investigator>
      <last_name>Monica Vetter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janna Espinosa</last_name>
      <email>Janna.Espinosa@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Theresa Werner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Gabel</last_name>
      <email>AM7BD@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Kari Ring, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Moore</last_name>
      <email>deborah.moore@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Krista Pfaendler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

